Stay updated with breaking news from Ichnos Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The "Global Dermatology Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering....
The FDA announced several regulatory actions the past few weeks. Here is an overview of decisions that may be relevant to your practice.
/PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific antibodies in oncology, today announced...
/PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific immune cell engager antibodies in...
Patients with moderate to severe atopic dermatitis showed promising results during and up to 20 weeks after treatment in a clinical trial evaluating rocatinlimab, according to a study. “I think [rocatinlimab] will be the next huge, big advance,” Emma Guttman-Yassky, MD, PhD, the Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the